论文部分内容阅读
目的观察舌下含服粉尘螨滴剂治疗变应性鼻炎的疗效及安全性。方法将124例尘螨过敏为主的变应性鼻炎患者,随机分为舌下含服免疫治疗(SLIT)+药物的观察组和单纯药物应用对照组,每组62例。前者以标准化粉尘螨滴剂舌下含服免疫治疗,严重时辅以对症药物治疗;对照组以糠酸莫米松鼻喷剂及孟鲁斯特对症治疗。2组患者每月回访1次,最少随访半年。观察并记录治疗后症状得分、药物评分及不良反应情况。半年后综合评价患者主观症状、用药及治疗满意度情况。结果观察组与对照组比较,其半年后症状得分、药物评分、满意度均明显高于对照组,差异均有统计学意义(P<0.05)。2组均有部分患者出现了一定程度的不良反应。结论舌下含服粉尘螨滴剂治疗对尘螨过敏的变应性鼻炎患者,症状改善较为明显,但变应性鼻炎是一种慢性疾病,为确保疗效,需对治疗过程加以管理,提高依从性,对治疗中的不良反应给予关注。
Objective To observe the efficacy and safety of sublingual dust mite drops in the treatment of allergic rhinitis. Methods A total of 124 patients with allergic rhinitis with dust mite allergy were randomly divided into observation group with sublingual immunotherapy (SLIT) + and control group with drug alone, with 62 cases in each group. The former with standardized dust mite drops sublingual immunotherapy, with severe symptomatic drug treatment; the control group to mometasone furoate nasal spray and montelukast symptomatic treatment. Two groups of patients visited once a month, at least six months follow-up. Observe and record symptom scores, drug scores and adverse reactions after treatment. Six months after a comprehensive evaluation of patients with subjective symptoms, medication and treatment satisfaction. Results Compared with the control group, the symptom score, drug score and satisfaction of the observation group and the control group were significantly higher than those of the control group, the difference was statistically significant (P <0.05). Some patients in both groups showed a certain degree of adverse reactions. Conclusion The treatment of allergic rhinitis sensitized to dust mite by sublingual d.citrazane drops is more obvious, but allergic rhinitis is a chronic disease. In order to ensure the curative effect, it is necessary to manage the treatment process and improve compliance Sexual, pay attention to the adverse reaction in treatment.